Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 SEK | +0.27% | -2.08% | +40.15% |
Mar. 13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
Feb. 21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
Business Summary
Number of employees: 11
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Gene Therapies
100.0
%
| 84 | 100.0 % | 27 | 100.0 % | -68.23% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 84 | 100.0 % | 27 | 100.0 % | -68.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 22-09-26 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 20-10-11 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 17-12-31 |
Karin Agerman
CTO | Chief Tech/Sci/R&D Officer | 51 | 17-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 20-12-31 |
Director/Board Member | 59 | 19-12-31 | |
Director/Board Member | 54 | 14-09-30 | |
Per Lundin
BRD | Director/Board Member | 41 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,801,197 | 13,769,476 ( 69.54 %) | 0 | 69.54 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+40.15% | 6.81M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- COMBI Stock
- Company CombiGene AB